456 related articles for article (PubMed ID: 30541187)
41. ADP induces desensitisation of equine platelet aggregation responses: studies using ADP beta S, a stable analogue of ADP.
Poole AW; Heath MF; Evans RJ
Res Vet Sci; 1993 Mar; 54(2):235-43. PubMed ID: 8460266
[TBL] [Abstract][Full Text] [Related]
42. Nucleoside triphosphates inhibit ADP, collagen, and epinephrine-induced platelet aggregation: role of P2Y₁ and P2Y₁₂ receptors.
Aslam M; Sedding D; Koshty A; Santoso S; Schulz R; Hamm C; Gündüz D
Thromb Res; 2013 Nov; 132(5):548-57. PubMed ID: 24071464
[TBL] [Abstract][Full Text] [Related]
43. Differential effects of adenine nucleotide analogues on shape change and aggregation induced by adnosine 5-diphosphate (ADP) in human platelets.
Park HS; Hourani SM
Br J Pharmacol; 1999 Jul; 127(6):1359-66. PubMed ID: 10455285
[TBL] [Abstract][Full Text] [Related]
44. Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk.
van der Meijden PE; Feijge MA; Giesen PL; Huijberts M; van Raak LP; Heemskerk JW
Thromb Haemost; 2005 Jun; 93(6):1128-36. PubMed ID: 15968399
[TBL] [Abstract][Full Text] [Related]
45. Distinct role of Pyk2 in mediating thromboxane generation downstream of both G12/13 and integrin αIIbβ3 in platelets.
Kim S; Cipolla L; Guidetti G; Okigaki M; Jin J; Torti M; Kunapuli SP
J Biol Chem; 2013 Jun; 288(25):18194-203. PubMed ID: 23640884
[TBL] [Abstract][Full Text] [Related]
46. Pharmacodynamic profile of antiplatelet agents: marked differences between single versus costimulation with platelet activators.
Graff J; Klinkhardt U; Harder S
Thromb Res; 2004; 113(5):295-302. PubMed ID: 15183041
[TBL] [Abstract][Full Text] [Related]
47. Inhibitory Effects of P2Y12 Receptor Antagonist on PAR1- and PAR4-AP-Induced Platelet Aggregation in Patients with Stroke or TIA.
Kamada A; Shimizu M; Oura K; Yoshida M; Tsuda K; Oi K; Ishigaku Y; Natori T; Narumi S; Itabashi R; Maeda T; Terayama Y
J Stroke Cerebrovasc Dis; 2021 Mar; 30(3):105547. PubMed ID: 33360254
[TBL] [Abstract][Full Text] [Related]
48. Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
Iyú D; Glenn JR; White AE; Fox SC; van Giezen H; Nylander S; Heptinstall S
Thromb Haemost; 2011 Jan; 105(1):96-106. PubMed ID: 20941457
[TBL] [Abstract][Full Text] [Related]
49. Effects of P2Y(1) and P2Y(12) receptor antagonists on ADP-induced shape change of equine platelets: comparison with human platelets.
Mateos-Trigos G; Evans RJ; Heath MF
Platelets; 2002; 13(5-6):285-92. PubMed ID: 12189014
[TBL] [Abstract][Full Text] [Related]
50. The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets.
Bambace NM; Levis JE; Holmes CE
Platelets; 2010; 21(2):85-93. PubMed ID: 20063989
[TBL] [Abstract][Full Text] [Related]
51. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.
Storey RF; Wilcox RG; Heptinstall S
Platelets; 2002 Nov; 13(7):407-13. PubMed ID: 12487788
[TBL] [Abstract][Full Text] [Related]
52. Thrombin-induced platelet endostatin release is blocked by a proteinase activated receptor-4 (PAR4) antagonist.
Ma L; Hollenberg MD; Wallace JL
Br J Pharmacol; 2001 Oct; 134(4):701-4. PubMed ID: 11606309
[TBL] [Abstract][Full Text] [Related]
53. Adenosine diphosphate receptors on blood platelets: potential new targets for antiplatelet therapy.
Rozalski M; Nocun M; Watala C
Acta Biochim Pol; 2005; 52(2):411-5. PubMed ID: 15912207
[TBL] [Abstract][Full Text] [Related]
54. Activation of the alpha(2A)-adrenoceptor mediates deceleration of the deaggregation component of the response to ADP or 5-HT in human platelets in vitro.
Maayani S; Schwarz T; Craddock-Royal B; Tagliente TM
Platelets; 2001 Sep; 12(6):359-75. PubMed ID: 11672475
[TBL] [Abstract][Full Text] [Related]
55. Protease-activated receptor-4 (PAR4) variant influences on platelet reactivity induced by PAR4-activating peptide through altered Ca
Morikawa Y; Kato H; Kashiwagi H; Nishiura N; Akuta K; Honda S; Kanakura Y; Tomiyama Y
Thromb Res; 2018 Feb; 162():44-52. PubMed ID: 29289806
[TBL] [Abstract][Full Text] [Related]
56. A critical role of thrombin/PAR-1 in ADP-induced platelet secretion and the second wave of aggregation.
Jiang L; Xu C; Yu S; Liu P; Luo D; Zhou Q; Gao C; Hu H
J Thromb Haemost; 2013 May; 11(5):930-40. PubMed ID: 23406164
[TBL] [Abstract][Full Text] [Related]
57. Interaction of human blood platelets with the 2',3'-dialdehyde and 2',3'-dialcohol derivatives of adenosine 5'-diphosphate and adenosine 5'-triphosphate.
Pearce PH; Wright JM; Egan CM; Scrutton MC
Eur J Biochem; 1978 Aug; 88(2):543-54. PubMed ID: 689037
[TBL] [Abstract][Full Text] [Related]
58. Impaired activation of murine platelets lacking G alpha(i2).
Jantzen HM; Milstone DS; Gousset L; Conley PB; Mortensen RM
J Clin Invest; 2001 Aug; 108(3):477-83. PubMed ID: 11489941
[TBL] [Abstract][Full Text] [Related]
59. Protease-activated receptor 1 (PAR1) signalling desensitization is counteracted via PAR4 signalling in human platelets.
Fälker K; Haglund L; Gunnarsson P; Nylander M; Lindahl TL; Grenegård M
Biochem J; 2011 Jun; 436(2):469-80. PubMed ID: 21391917
[TBL] [Abstract][Full Text] [Related]
60. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice.
Léon C; Hechler B; Freund M; Eckly A; Vial C; Ohlmann P; Dierich A; LeMeur M; Cazenave JP; Gachet C
J Clin Invest; 1999 Dec; 104(12):1731-7. PubMed ID: 10606627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
